In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovation

Set Alert for Innovation

Building The Biotech City: Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?

The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.

US States Growth BioPharmaceutical

Latest From Innovation

C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute

In case you missed it: catch up with snippets from interviews recently published by In Vivo.

C-Suite Speaks Market Access

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

Outlook 2020 Artificial Intelligence

Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Innovation Pricing Strategies

The SMA Market: Assessing The Unknowns

The introductions of Spinraza and Zolgensma in SMA offer new insights into how to address neurodegenerative diseases. But more real world evidence is needed.

Innovation Rare Diseases

The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI

The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.

Digital Health Research and Development Strategies

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology
See All
UsernamePublicRestriction

Register